Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group MA.12 -- Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF or AC Adjuvant Chemotherapy

Keilty D, Buchanan M, Ntapolias K, Aleynikova O, Tu D, Li X, Shepherd L, Bramwell V, Basik M. RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial. PLoS ONE 8: e81740, 2013.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0081740

__________________________________

Canadian Cancer Trials Group CO.17 -- A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean EC, Zalcberg JR, Simes J, Moore MJ, Tebbutt N, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Hazel Gv, Lee U, Haq R, Virk S, Tu D, Lorimer IAJ. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from Canadian Cancer Trials Group / AGITG CO.17 (ONLINE). Clin Cancer Res 2013.

http://clincancerres.aacrjournals.org/content/early/2013/11/09/1078-0432.CCR-13-0606

Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RPW, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer (ONLINE). Br J Cancer 2013.

http://www.nature.com/bjc/journal/vaop/ncurrent/full/bjc2013753a.html